Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Allergic Rhinitis - Pipeline Review, H1 2018, provides an overview of the Allergic Rhinitis (Respiratory) pipeline landscape.
Allergic rhinitis is an allergic reaction that happens when immune system overreacts to substances that is inhaled. An allergen is something that triggers an allergy. When a person with allergic rhinitis breathes in an allergen such as pollen, mold, animal dander, or dust, the body releases chemicals that cause allergy symptoms. Symptoms of allergic rhinitis include stuffy runny nose, sneezing, swollen eyelids, itchy mouth, throat, ears.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Allergic Rhinitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Allergic Rhinitis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Allergic Rhinitis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Allergic Rhinitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 7, 11, 2, 14 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 3 and 3 molecules, respectively.
Allergic Rhinitis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Rhinitis (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Allergic Rhinitis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Allergic Rhinitis (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Allergic Rhinitis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Rhinitis (Respiratory)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Allergic Rhinitis (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Allergic Rhinitis (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Allergic Rhinitis - Overview
Allergic Rhinitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Allergic Rhinitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Allergic Rhinitis - Companies Involved in Therapeutics Development
Accolade Pharmaceuticals LLC
AFFiRiS AG
ALK-Abello AS
AlleCures Inc
ASIT Biotech SA
Chong Kun Dang Pharmaceutical Corp
Chrysalis BioTherapeutics Inc
Fountain Biopharma Inc
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
HAL Allergy BV
Intrommune Therapeutics
Laboratorios LETI SL
Paradigm Biopharmaceuticals Ltd
Sanofi
Stallergenes Greer plc
Taiho Pharmaceutical Co Ltd
Xencor Inc
Allergic Rhinitis - Drug Profiles
(azelastine hydrochloride + budesonide) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(fexofenadine hydrochloride + phenylephrine hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(mometasone furoate + olopatadine hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
854-A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Allergic Rhinitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Asthma and Perennial Allergic Rhinitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for House Dust Mite Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergens for Perennial Allergic Rhinitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
arabinogalactan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
B-244 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bepotastine besilate SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BM-41 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBP-174 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPC-888 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FB-825 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gp-ASIT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hdm-ASIT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KR-62980 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lactococcus lactis G121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
levocabastine hydrochloride + mometasone furoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Seasonal Allergic Rhinitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NVP-1703 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pentosan polysulfate sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rag-ASIT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
short ragweed pollen (Ambrosia artemisiifolia) allergen extract ODT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Allergic Rhinitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize CRTH2 for Inflammation and Respiratory Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Seasonal Allergic Rhinitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize H1 and H3 Receptor for Allergic Rhinitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize HRH1 for Allergic Rhinitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PGD2 Synthase for Asthma and Allergic Rhinitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STG-120 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SYM-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAS-205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Asthma and Allergic Rhinitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target IgE for Allergic Rhinitis and Asthma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XmAb-7195 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Zafi-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergic Rhinitis - Dormant Projects
Allergic Rhinitis - Discontinued Products
Allergic Rhinitis - Product Development Milestones
Featured News & Press Releases
Mar 05, 2018: Glenmark Pharmaceuticals Presents New Data on Ryaltris, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis at the AAAAI/WAO Joint Congress
Feb 21, 2018: New medicine for house dust mite allergic rhinitis and allergic asthma now available in France
Feb 16, 2018: Shionogi Got Approval of Partial Change Application in Dosage and Administration in Japan of Actair for Allergen Immunotherapy of Pediatric Allergic Rhinitis Caused by House Dust Mites
Feb 16, 2018: Torii Receives Approval for Additional Dosage and Administration for Pediatric Indication for MITICURE House Dust Mite Sublingual Tablets
Jan 11, 2018: New Treatment for House Dust Mite (HDM) - Induced Allergic Rhinitis Now Available in US
Dec 13, 2017: Glenmark Pharmaceuticals Announces Top-Line Results from a Phase 3 Safety Study Evaluating Ryaltris in Patients with Perennial Allergic Rhinitis
Nov 30, 2017: Newly published Phase IIb clinical results with gp-ASIT+ in the ALLERGY journal highlight outstanding clinical and remarkable immunological effects
Oct 23, 2017: Glenmark Pharmaceuticals Presenting New Data from Respiratory Portfolio at the ACAAI Annual Scientific Meeting 2017
Oct 12, 2017: ASIT biotech announces the Publication of Its First Clinical Data with gp-ASIT+ in the Journal of Allergy and Clinical Immunology
Sep 26, 2017: Stallergenes Greer Advances Its House Dust Mite Allergy Pipeline with Acceptance Of Regulatory Submission And New Market Approval
Jul 03, 2017: ASIT biotech Presented the Immunogenicity Data of the gp-ASIT+ Phase III Clinical Study for the Treatment of Grass Pollen Rhinitis at EAACI 2017
Jun 19, 2017: ASIT biotech Discloses Comments from the Paul Ehrlich Institute and Presents Detailed Results on the Phase III Clinical Study of gp-ASIT+ at EAACI 2017
May 16, 2017: Paradigm’s preclinical hay fever trial: peer-reviewed and published in leading scientific journal
Apr 16, 2017: ACARIZAX approved in Europe for use in adolescent patients with house dust mite-induced allergic rhinitis
Apr 04, 2017: ASIT Biotech Announces that it Has Achieved the Primary Endpoint of the Phase I/IIa Clinical Trial with its hdm-ASIT+ Product Candidate for House Dust Mite Rhinitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Allergic Rhinitis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Allergic Rhinitis - Pipeline by Accolade Pharmaceuticals LLC, H1 2018
Allergic Rhinitis - Pipeline by AFFiRiS AG, H1 2018
Allergic Rhinitis - Pipeline by ALK-Abello AS, H1 2018
Allergic Rhinitis - Pipeline by AlleCures Inc, H1 2018
Allergic Rhinitis - Pipeline by ASIT Biotech SA, H1 2018
Allergic Rhinitis - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018
Allergic Rhinitis - Pipeline by Chrysalis BioTherapeutics Inc, H1 2018
Allergic Rhinitis - Pipeline by Fountain Biopharma Inc, H1 2018
Allergic Rhinitis - Pipeline by GlaxoSmithKline Plc, H1 2018
Allergic Rhinitis - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2018
Allergic Rhinitis - Pipeline by HAL Allergy BV, H1 2018
Allergic Rhinitis - Pipeline by Intrommune Therapeutics, H1 2018
Allergic Rhinitis - Pipeline by Laboratorios LETI SL, H1 2018
Allergic Rhinitis - Pipeline by Paradigm Biopharmaceuticals Ltd, H1 2018
Allergic Rhinitis - Pipeline by Sanofi, H1 2018
Allergic Rhinitis - Pipeline by Stallergenes Greer plc, H1 2018
Allergic Rhinitis - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2018
Allergic Rhinitis - Pipeline by Xencor Inc, H1 2018
Allergic Rhinitis - Dormant Projects, H1 2018
Allergic Rhinitis - Dormant Projects, H1 2018 (Contd..1), H1 2018
Allergic Rhinitis - Dormant Projects, H1 2018 (Contd..2), H1 2018
Allergic Rhinitis - Dormant Projects, H1 2018 (Contd..3), H1 2018
Allergic Rhinitis - Dormant Projects, H1 2018 (Contd..4), H1 2018
Allergic Rhinitis - Dormant Projects, H1 2018 (Contd..5), H1 2018
Allergic Rhinitis - Dormant Projects, H1 2018 (Contd..6), H1 2018
Allergic Rhinitis - Discontinued Products, H1 2018
Allergic Rhinitis - Discontinued Products, H1 2018 (Contd..1), H1 2018
List of Figures
Number of Products under Development for Allergic Rhinitis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
